<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818866</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00178971-a</org_study_id>
    <nct_id>NCT04818866</nct_id>
  </id_info>
  <brief_title>International Study of Inflammation in COVID-19</brief_title>
  <acronym>ISIC</acronym>
  <official_title>The International Study of Inflammation in COVID-19: A Prospective Multi-Center Observational Study Examining the Role of Biomarkers of Inflammation in Predicting Covid-19 Related Outcomes in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multi-center observational study which purpose is to evaluate the&#xD;
      ability of blood-based inflammatory markers to risk-stratify patients hospitalized for&#xD;
      Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator&#xD;
      receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate&#xD;
      dehydrogenase and interleukin-6.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All consecutive patients hospitalized specifically for Covid-19 at the University of Michigan&#xD;
      in Ann Arbor from February 1st, 2020 to date are included. Other participating centers will&#xD;
      enroll patients depending on their variable capacity. Patients with a positive test for&#xD;
      SARS-CoV-2 but hospitalized for non-Covid-19 reasons were excluded. Blood-based biomarkers&#xD;
      including soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP),&#xD;
      procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6 are measured in&#xD;
      samples collected within 48 hours of presentation. The primary outcome of the study is the&#xD;
      composite endpoint of in-hospital mortality, need for mechanical ventilation and need for&#xD;
      renal replacement therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital incidence of death, need for mechanical ventilation and need for renal replacement therapy</measure>
    <time_frame>during COVID91 related hospitalization, up to 6 months</time_frame>
    <description>Composite outcome of death, need for mechanical ventilation, need for renal replacement therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>within 6 months</time_frame>
    <description>Per KDIGO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Events</measure>
    <time_frame>within 6 months</time_frame>
    <description>In-hospital new diagnosis heart failure, arrhythmia, myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>within 6 months</time_frame>
    <description>In-hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>within 6 months</time_frame>
    <description>In-hospital renal replacement therapy or dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>within 6 months</time_frame>
    <description>Respiratory failure requiring mechanical ventilation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Covid19</condition>
  <condition>Outcome, Fatal</condition>
  <condition>Respiratory Failure</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Patients hospitalized for Covid-19</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase</intervention_name>
    <description>Biomarkers of inflammation</description>
    <arm_group_label>Patients hospitalized for Covid-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma or serum samples collected within 48 hours of presentation.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients hospitalized primarily for Covid-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive SARS-CoV-2 test result&#xD;
&#xD;
          -  Covid-19 as the primary reason for hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalized primarily for non-Covid-19 reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salim S Hayek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salim S Hayek, MD</last_name>
    <phone>734-936-3500</phone>
    <email>shayek@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pennelope K Kunkle</last_name>
    <phone>631-678-2935</phone>
    <email>penegonz@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pennelope K Kunkle</last_name>
      <phone>734-936-3500</phone>
      <email>penegonz@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Salim S Hayek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.</citation>
    <PMID>32354367</PMID>
  </reference>
  <results_reference>
    <citation>Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22.</citation>
    <PMID>32963090</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Salim S. Hayek</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>SuPAR</keyword>
  <keyword>CRP</keyword>
  <keyword>D-dimer</keyword>
  <keyword>Ferritin</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>Procalcitonin</keyword>
  <keyword>lactate dehydrogenase</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to consent waiver, individual participant data cannot be shared with investigators outside the University of Michigan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

